>Why does BRL need to purchase ordinary (non-XR) Adderall from Shire when BRL is already selling such a product? That’s the one part of the agreement I don’t understand.<
After thinking about this deal for 24 hours, I now think Barr offered to take non-XR Adderall off Shire’s hands as an inducement to get the other terms in the deal. The product has very small sales and will not be detailed by BRL or anyone else.
What I find amusing in all this is that that ordinary Adderall is a great product. It’s a testament to pharma’s marketing muscle that this product was so quickly and easily eclipsed by Adderall XR.
Market Data 
Markets 
AI
